Coherus BioSciences Provides Update on IPRs

REDWOOD CITY, Calif., June 13, 2016 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has received a favorable decision from the Patent Trial and...